Armata Pharmaceuticals, Inc.
ARMP- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000921114
No open-market purchases or sales by Armata Pharmaceuticals, Inc. insiders were filed in the last 90 days; 53 institutions reported holding it in 13F filings for Q2 2026, worth $32.3M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Armata Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Armata Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Birx Deborah | Chief Executive Officer | 198,417 | Jul 14, 2026 | 3 |
| Gilmer Daniel B. | Director | – | Apr 28, 2026 | 1 |
| Kyme Pierre | Chief Business Officer | 9,461 | Mar 17, 2026 | 2 |
| Patti Joseph M | Director | – | Mar 11, 2026 | 1 |
| Haimovitz Jules | Director | – | Mar 11, 2026 | 1 |
| Odysseas Kostas D | Director | – | Mar 11, 2026 | 1 |
| Schlesinger Sarah J. | Director | – | Mar 11, 2026 | 1 |
| Kramer Robin | Director | – | Mar 11, 2026 | 1 |
| Peterson Todd C. | Director | – | Mar 11, 2026 | 1 |
| House David Duane | SVP, Finance, and PFO | – | Mar 11, 2026 | 1 |
| Rychlik Richard | Corporate Controller and PFO | 10,000 | Mar 18, 2024 | 0 |
| Innoviva, Inc. | Director, 10% Owner | 16,365,969Indirect | Jan 12, 2023 | 0 |
| Innoviva Strategic Opportunities LLC | Director, 10% Owner | 16,365,969Indirect | Jan 12, 2023 | 0 |
| Patrick Todd | Director | – | Apr 15, 2022 | 0 |
| Morris Duane Alfred | VP of Operations | – | Apr 15, 2022 | 0 |
| Varnum Brian | President and CEO | – | Apr 15, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 12, 2023 (view filing)9:21 PM ET | Jan 10 | 2 days | Innoviva, Inc. and 1 otherDirector, 10% Owner | PPurchase | +19.7M | – | – | – | DerivativePrice outlier |
| Apr 1, 2022 (view filing)4:52 PM ET | Mar 31 | 1 day | Innoviva, Inc. and 1 otherDirector, 10% Owner | PPurchase | +5.39M | $5.00 | +$26.9M | +49.0%16.4M after | |
| Apr 1, 2022 (view filing)4:52 PM ET | Mar 31 | 1 day | Innoviva, Inc. and 1 otherDirector, 10% Owner | PPurchase | +2.69M | $0.00 | $0 | –2.69M after | Derivative |
| Feb 11, 2022 (view filing)6:56 PM ET | Feb 9 | 2 days | Innoviva, Inc. and 1 otherDirector, 10% Owner | PPurchase | +3.61M | $5.00 | +$18.1M | +49.1%11.0M after | |
| Feb 11, 2022 (view filing)6:56 PM ET | Feb 9 | 2 days | Innoviva, Inc. and 1 otherDirector, 10% Owner | PPurchase | +1.81M | $5.00 | +$9.04M | –1.81M after | Derivative |
| Nov 1, 2021 (view filing)2:20 PM ET | Oct 29 | 3 days | Innoviva, Inc. and 1 otherDirector, 10% Owner | PPurchase | +1.21M | $3.30 | +$4.00M | +19.7%7.37M after |